IL6R and rheumatoid arthritis: TCZ, an IL-6R antibody (Ab) that globally blocks IL-6 activities through IL-6R-α and sIL-6R, is associated with a significant reduction in the QTc interval in patients with rheumatoid arthritis (RA) [91].